

NEOPROBE 4th QUARTER AND FULL YEAR EARNINGS CONFERENCE CALL INVITATION
Conference Call Scheduled for 11:00 AM ET, Wednesday, March 11th

DUBLIN, OHIO – March 5, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced it would report its financial results for the fourth quarter and full year of 2008 on Tuesday, March 10, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community scheduled for the following morning, Wednesday, March 11, 2009, at 11:00 AM ET.

Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the company's results for the fourth quarter and full year of 2008 during the conference call scheduled for 11:00 AM ET, Wednesday, March 11, 2009. The conference call can be accessed as follows:

Conference Call Information			
TO PARTICIPATE LIVE:		TO LISTEN TO A REPLAY:	
Date:	Mar. 11, 2009	Available until:	Mar. 18, 2009
Time:	11:00 AM ET	Toll-free (U.S.) Dial in # :	877-660-6853
		International Dial in # :	201-612-7415
Toll-free (U.S.) Dial in # :	877-407-8033	Replay Passcodes:	
International Dial in # :	201-689-8033	Account #:	286
		Conference ID #:	315934

In addition, Neoprobe announced that it had engaged The Shoreham Group LLC as its investor relations firm. The Shoreham Group brings over 25 years of experience in dealing with Wall Street and investors to bear in serving the Company. Investors may contact Tim Ryan at The Shoreham Group LLC by telephone at 646 342 6199 or by e-mail at tryan@shorehamgroupllc.com.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000[®] line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix[®] line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[®] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com